Authors:
Holst-Hansen, C
Low, JA
Stephens, RW
Johnson, MD
Carmeliet, P
Frandsen, TL
Brunner, N
Dickson, RB
Citation: C. Holst-hansen et al., Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat, BREAST CANC, 68(3), 2001, pp. 225-237
Authors:
Frandsen, TL
Holst-Hansen, C
Nielsen, BS
Christensen, IJ
Nyengaard, JR
Carmeliet, P
Brunner, N
Citation: Tl. Frandsen et al., Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) fin the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model, CANCER RES, 61(2), 2001, pp. 532-537
Authors:
Ploug, M
Ostergaard, S
Gardsvoll, H
Kovalski, K
Holst-Hansen, C
Holm, A
Ossowski, L
Dano, K
Citation: M. Ploug et al., Peptide-derived antagonists of the urokinase receptor. Affinity maturationby combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation, BIOCHEM, 40(40), 2001, pp. 12157-12168
Authors:
Holst-Hansen, C
Stephens, RW
Johannessen, BE
Jensen, PB
Brunner, N
Citation: C. Holst-hansen et al., Plasma Escherichia coli beta-galactosidase as a marker of tumor burden andresponse to experimental anti-neoplastic therapy in nude mice xenografted with lacZ transduced human tumor cells, LAB INV, 80(5), 2000, pp. 719-724
Authors:
Holst-Hansen, C
Hamers, MJAG
Johannessen, BE
Brunner, N
Stephens, RW
Citation: C. Holst-hansen et al., Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies, BR J CANC, 81(2), 1999, pp. 203-211
Authors:
Holst-Hansen, C
Brunner, N
Johannessen, BE
Felding, J
Stephens, RW
Citation: C. Holst-hansen et al., A new immunocapture assay for Escherichia coli beta-galactosidase for in vivo studies of lacZ-transduced tumor cells, LAB INV, 78(12), 1998, pp. 1643-1644